Oxnard-based CURE Pharmaceutical announced plans to acquire formulation technology company Chemistry Holdings Inc. in an all-stock transaction. The deal will allow the former to gain IP and rights to the later’s pharma technology, including a chewable delivery system that will complement its CUREfilm platform — an oral thin film used to deliver active ingredients.
“[The] combined technologies expand the CUREfilm platform to enable delivery of a wider range of active ingredients at higher doses and create a highly versatile platform for both immediate and controlled-release drug delivery,” according to CURE.
CEO Rob Davidson said the deal “will create a pioneering drug delivery engine with the promise to transform patient experience and wellness.”
